



## Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020)

October 14, 2020

SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design *de novo* protein therapeutics, today announced the acceptance of a preclinical data abstract on its lead therapeutic candidate, NL-201, at the Society for Immunotherapy of Cancer's 35<sup>th</sup> Anniversary Annual Meeting (SITC 2020) taking place November 9 to November 14, 2020 in a virtual format.

Details of the poster presentation are as follows:

**Title:** NL-201, a *de novo* IL-2/IL-15 agonist, demonstrates enhanced *in vivo* antitumor activity in combination with multiple cancer immunotherapies

**Abstract:** 576

**Authors:** Carl Walkey, Ryan Swanson, Kevin Yu, Umut Ulge, Daniel Silva, and Jonathan Drachman of Neoleukin Therapeutics

### Virtual Poster Hall:

November 11 – November 14, 9 a.m.- 5 p.m. EST.

### ePoster presentation times including live Q&A:

Thursday, November 12 from 4:50-5:20 p.m. EST and

Saturday, November 14 from 1-1:30 p.m. EST

### About NL-201

NL-201 is a *de novo* receptor agonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without any bias toward cells expressing the alpha receptor subunit (CD25). Previously presented preclinical data has demonstrated the ability of NL-201 to stimulate and expand CD8+ and NK cells at very low doses with minimal impact on immunosuppressive regulatory T cells.

### About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using *de novo* protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: [www.neoleukin.com](http://www.neoleukin.com).

### Safe Harbor / Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, planned development activities and timelines, use and adequacy of cash reserves and the potential benefits of the company's product candidates and platform. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of such forward-looking statements include but are not limited to statements regarding the therapeutic properties and potential of the company's *de novo* protein design technology. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company's cash forecasts, the company's ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company's clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin's business and its financial results are detailed under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

### Contacts:

#### Media

Julie Rathbun

206-769-9219

[jrathbun@neoleukin.com](mailto:jrathbun@neoleukin.com)

#### Investors

Solebury Trout

Brian Korb

646-378-2923

[bkorb@troutgroup.com](mailto:bkorb@troutgroup.com)



Source: Neoleukin Therapeutics, Inc.